UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

The potential of proteasome inhibitors in cancer therapy

Expert opinion on investigational drugs, 2008-06, Vol.17 (6), p.879-895

2008

Volltextzugriff (PDF)

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Blood, 2007-03, Vol.109 (5), p.2100-2105

2007

Volltextzugriff (PDF)

Angiogenesis in multiple myeloma

European journal of cancer (1990), 2006-07, Vol.42 (11), p.1581-1590

2006

Volltextzugriff (PDF)

Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK

British journal of haematology, 2007-08, Vol.138 (4), p.446-458

2007

Volltextzugriff (PDF)

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma

European journal of haematology, 2008-02, Vol.80 (2), p.133-142

2008

Volltextzugriff (PDF)

The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma

Haematologica (Roma), 2006-02, Vol.91 (2), p.248-251

2006

Volltextzugriff (PDF)

The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases

European journal of haematology, 2012-05, Vol.88 (5), p.406-415

2012

Volltextzugriff (PDF)

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma

European journal of haematology, 2006-01, Vol.76 (1), p.42-50

2006

Volltextzugriff (PDF)

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma

Blood, 2009-11, Vol.114 (22), p.2802-2802

2009

Volltextzugriff (PDF)

Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy

Blood, 2008-11, Vol.112 (11), p.2721-2721

2008

Volltextzugriff (PDF)

Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma

Anti-cancer drugs, 2006-08, Vol.17 (7), p.763-769

2006

Volltextzugriff (PDF)

BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma

European journal of haematology, 2010-08, Vol.85 (2), p.99-107

2010

Volltextzugriff (PDF)

The Proteasome Inhibitor BSc2118 Causes Growth Inhibition, Cell Cycle Arrest and Cyclin D1 Degradation in Mantle Cell Lymphoma Cell Lines

Blood, 2007-11, Vol.110 (11), p.1401-1401

2007

Volltextzugriff (PDF)

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma

Blood, 2007-11, Vol.110 (11), p.1475-1475

2007

Volltextzugriff (PDF)

Histone Deacetylase Inhibitors Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma and Reduce VEGF Production

Blood, 2005-11, Vol.106 (11), p.4817-4817

2005

Volltextzugriff (PDF)

Angiogenesis in multiple myeloma: 160 years of Multiple Myeloma: Progress and Challenges

European journal of cancer (1990), 2006, Vol.42 (11), p.1581-1590

2006

Volltextzugriff (PDF)

Serum Levels of Total-RANKL in Multiple Myeloma

Clinical lymphoma & myeloma, 2009-12, Vol.9 (6), p.430-435

2009

Volltextzugriff (PDF)

Serum Total-RANKL Is Elevated in Patients with Multiple Myeloma, Increases with ISS Stage and Decreases after Induction Therapy

Blood, 2005-11, Vol.106 (11), p.2511-2511

2005

Volltextzugriff (PDF)

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma

Blood, 2006-11, Vol.108 (11), p.2509-2509

2006

Volltextzugriff (PDF)

Bortezomib Inhibits Human Osteoclastogenesis

Blood, 2006-11, Vol.108 (11), p.1395-1395

2006

Volltextzugriff (PDF)

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma

Blood, 2006-11, Vol.108 (11), p.3475-3475

2006

Volltextzugriff (PDF)

Treatment of Bortezomib Increases Osteoblast Function in Patients with Multiple Myeloma

Blood, 2005-11, Vol.106 (11), p.3457-3457

2005

Volltextzugriff (PDF)

Kosten-Erlös-Defizit der ambulanten Versorgung von Bagatellverletzungen in der Notaufnahme

Unfallchirurgie (Heidelberg, Germany), 2023-06, Vol.126 (6), p.433-440

2023

Volltextzugriff (PDF)

Manual vs. integrated automatic load-distributing band CPR with equal survival after out of hospital cardiac arrest. The randomized CIRC trial

Resuscitation, 2014-06, Vol.85 (6), p.741-748

2014

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Humans
(26)
Emergency Medicine
(13)
General & Internal Medicine
(13)
Critical Care Medicine
(11)
Emergency
(11)
Cardiac Arrest
(9)
Cardiopulmonary Resuscitation - Methods
(9)
Female
(9)
Male
(9)
Cardiopulmonary Resuscitation
(8)
Out-Of-Hospital Cardiac Arrest - Therapy
(8)
Adult
(7)
Hematology
(7)
Middle Aged
(7)
Out-Of-Hospital Cardiac Arrest - Mortality
(7)
Aged
(6)
Biological And Medical Sciences
(6)
Medical Sciences
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The potential of proteasome inhibitors in cancer therapy

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Angiogenesis in multiple myeloma

Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma

The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma

The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma

Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy

Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma

BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma

The Proteasome Inhibitor BSc2118 Causes Growth Inhibition, Cell Cycle Arrest and Cyclin D1 Degradation in Mantle Cell Lymphoma Cell Lines

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma

Histone Deacetylase Inhibitors Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma and Reduce VEGF Production

Angiogenesis in multiple myeloma: 160 years of Multiple Myeloma: Progress and Challenges

Serum Levels of Total-RANKL in Multiple Myeloma

Serum Total-RANKL Is Elevated in Patients with Multiple Myeloma, Increases with ISS Stage and Decreases after Induction Therapy

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma

Bortezomib Inhibits Human Osteoclastogenesis

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma

Treatment of Bortezomib Increases Osteoblast Function in Patients with Multiple Myeloma

Kosten-Erlös-Defizit der ambulanten Versorgung von Bagatellverletzungen in der Notaufnahme

International variation in survival after out-of-hospital cardiac arrest: A validation study of the Utstein template

Manual vs. integrated automatic load-distributing band CPR with equal survival after out of hospital cardiac arrest. The randomized CIRC trial

Suchergebnisse filtern